HOOKIPA Pharma Inc HOOK.OQ HOOK.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The New York City-based company is expected to report a 90.8% decrease in revenue to $3.375 million from $36.6 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for HOOKIPA Pharma Inc is for a loss of $1.04 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for HOOKIPA Pharma Inc is $7.00, above its last closing price of $1.34.
This summary was machine generated May 5 at 12:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments